ADXS-NEO: Personalized Therapies Targeting Neoantigens
Making Personalized Cancer Care a Reality
WORKING WITH AMGEN TO MAKE PERSONALIZED MEDICINE A REALITY
Advaxis’ Lm Technology™ is a versatile platform which is being utilized to create patient-specific immunotherapies to potentially treat a broad range of cancers by targeting tumor-specific mutations found in an individual patient’s tumor known as neoantigens. This approach is the ADXS- NEO program.
“Personalized Medicine” has long been a popular catch-phrase for pharmaceutical companies, but to date no company has delivered on the promise of a truly personalized therapy. ADXS-NEO creates a customized treatment with neoantigens specifically selected based on a biopsy of the patient’s tumor. Working in partnership with Amgen, we are proud to be developing a truly personalized solution for oncology patients.
LEADING DRUG CANDIDATES
ADXS-NEO is a customized cancer treatment with promising implications across several cancers. Through a parallel manufacturing system, the production of ADXS-NEO is designed to be easily scalable and timely for patients. Further details on the potential of ADXS-NEO can be found in a new white paper.
Developing the ADXS-NEO immunotherapy begins with a biopsy of the primary tumor and/or metastases, along with the patient’s normal cells, to identify non-synonymous mutations, or neoepitopes. These are then sent for exome sequencing, where a mutational map of the tumor is developed that can be used to select a set of neoepitopes most likely to be immunogenic.
Advaxis uses its Lm Technology™ to integrate coding sequences for these tumor-associated neoepitopes into a plasmid-based system that expresses them in the context of a fusion protein sequence including a fragment of the LLO molecule. The Lm vector is taken up by the antigen-presenting cells. Within the vector, large quantities of proteins with the mutated neoepitope are generated and secreted into the cytosol of the antigen-presenting cells, wherein they are processed and used to activate tumor-specific T cells, which can then find the cancer cells and destroy them. ADXS-NEO constructs also are designed to neutralize tumor protecting mechanisms by reducing the immune-suppressive activities of Tregs and myeloid-derived suppressor cells in the tumor microenvironment.
A Phase 1 clinical trial is currently ongoing.